Search for dissertations about: "ABCG2"

Showing result 1 - 5 of 11 swedish dissertations containing the word ABCG2.

  2. 1. ATP-Binding Cassette Efflux Transporters and Passive Membrane Permeability in Drug Absorption and Disposition

    Author : Pär Matsson; Per Artursson; Ulf Norinder; Peter Swaan; Uppsala universitet; []
    Keywords : Pharmaceutics; ATP-binding cassette; ABC transporter; P-gp; P-glycoprotein; ABCB1; BCRP; Breast cancer resistance protein; ABCG2; MRP2; Multidrug-resistance associated protein 2; ABCC2; Membrane permeability; Drug transport; Active transport; Passive diffusion; Multivariate data analysis; PLS; OPLS; QSAR; Galenisk farmaci;

    Abstract : Transport into and across the cells of the human body is a prerequisite for the pharmacological action of drugs. Passive membrane permeability and active transport mechanisms are major determinants of the intestinal absorption of drugs, as well as of the distribution to target tissues and the subsequent metabolism and excretion from the body. READ MORE

  4. 2. ATP-Binding-Cassette Transporters in Biliary Efflux and Drug-Induced Liver Injury

    Author : Jenny M. Pedersen; Per Artursson; Christel A. S. Bergström; Stefan Oswald; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; ABC transport protein; Pgp; P-glycoprotein; ABCB1; BCRP; breast cancer resistance protein; ABCG2; MRP2; multidrug resistance-associated protein 2; ABCC2; BSEP; bile salt export pump; ABCB11; sandwich cultured human hepatocytes; SCHH; drug-induced liver injury; DILI; multivariate data analysis; OPLS; Galenisk farmaci; Pharmaceutics;

    Abstract : Membrane transport proteins are known to influence the absorption, distribution, metabolism, excretion and toxicity (ADMET) of drugs. At the onset of this thesis work, only a few structure-activity models, in general describing P-glycoprotein (Pgp/ABCB1) interactions, were developed using small datasets with little structural diversity. READ MORE

  5. 3. TGF-beta signaling in cancer

    Author : Erik Johansson; Göteborgs universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; TGF-β; proliferation; cancer; tumor suppressor; diffuse-type gastric carcinoma; neuroblastoma; nuclear receptor TLX; cancer stem cell; angiogenesis; ABCG2; VHL; HIF2α; hypoxia; Smad3;

    Abstract : Transforming Growth Factor Beta (TGF-β) is a cytokine regulating a wide range of cellular processes such as proliferation, differentiation, and migration. At the early stages of cancer development TGF-β functions as a tumor suppressor, mainly due to its inhibitory effect on cellular growth, but during cancer progression, mutations in TGF-β signal components switches TGF-β into a promoter of cancer cell proliferation, survival and metastasis. READ MORE

  6. 4. Interindividual Variability of Drug Transport Proteins : Focus on Intestinal Pgp (ABCB1) and BCRP (ABCG2)

    Author : Gunilla Englund; Per Artursson; Håkan Melhus; Andreas Kindmark; Joseph W Polli; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmaceutics; membrane transport proteins; ATP-Binding Cassette Transporters; P-glycoprotein; Breast Cancer Resistance Protein; Interindividual variability; Galenisk farmaci; Pharmaceutics; Galenisk farmaci;

    Abstract : The appearance of adverse drug reactions is a common reason for hospitalization in Western countries. Research on underlying biological mechanisms for interindividual variability in drug response aims to better identify patients with exceptional genetic traits, disease conditions or risk of drug-drug interactions and thereby help to prevent adverse drug reactions. READ MORE

  7. 5. Influence of CYP3A enzymes and ABC transporters on the activity of tyrosine kinase inhibitors in chronic myeloid leukemia

    Author : Karin Skoglund; Henrik Gréen; Curt Peterson; Kourosh Lotfi; Staffan Hägg; Jörg Cammenga; Linköpings universitet; []
    Keywords : ;

    Abstract : The introduction of imatinib, a tyrosine kinase inhibitor (TKI), in the treatment of chronic myeloid leukemia (CML) was a major break-through and the first drug that was successfully designed to target the specific mechanism of a malignant disease. Imatinib still remains as the standard treatment of newly diagnosed CML patients although a second generation of TKIs has also been approved for first-line CML treatment. READ MORE